2020 International Congress of Diabetes and Metabolism

S5 Clinical diabetes and therapeutics 1 : Near-normal glucose control revisited On-Air Channel A	14:00~16:00 / Friday 18 September Chairman:Joong Yeol Park, Sin Gon Kim	Overview
Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach.
Neda Laiteerapong The University of Chicago, USA	5-1Lack of a legacy effect in patients with diabetes and cardiovascular disease
Chang Hee Jung University of Ulsan, Korea	5-2Early intensive combination therapy in T2DM: pros and cons
Hyuk Sang Kwon The Catholic University of Korea, Korea	5-3Strategy to achieve remission of type 2 diabetes
Roopa Mehta INCMNSZ, Mexico	5-4Do we need to use SGLT2i/GLP-1RA in well-controlled diabetes with increased CV risk?

S11 Clinical diabetes and therapeutics 2 : Controversies in the management of dyslipidemia in diabetes On-Air Channel A	09:00~11:00 / Saturday 19 September Chairman:Choon Hee Chung, Cheol-Young Park	Overview
Although optimal management of dyslipidemia is very important to reduce the risk for cardiovascular disease in patients with diabetes, several controversies still exist in this area. In this session, four speakers with extensive experience in the field of dyslipidemia will address the most pertinent controversies in lipid management and deliver the current evidence. In addition, the Korean CVD related data will be discussed. This session will provide further insights in management of dyslipidemia.
Beom Joon Kim Seoul National University, Korea	11-1What is the ideal cholesterol level after stroke or TIA in Korean diabetic patients?
Kwang Kon Koh Gachon University, Korea	11-2Strategies to overcome residual risk in statins era
Nam Hoon Kim Korea University, Korea	11-3Fish oil and cardiometabolic diseases
Seung-Hwan Lee The Catholic University of Korea, Korea	11-4Big data based CVD risk prediction model in Korea

Main symposia